Skip to content

SGM-101 tumor-targeted fluorescence endoscopy to enable discrimination of malignant from benign tissue in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia: a feasibility study

SGM-101 tumor-targeted fluorescence endoscopy to enable discrimination of malignant from benign tissue in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia: a feasibility study - SGM-T1

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53334
Enrollment
20
Registered
2023-03-06
Start date
2024-01-25
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polyp rectal cancer

Interventions

In total 20 patients will be included. The first 3 patients with large rectal polyps in the distal and mid-rectum scheduled for a local endoscopic en-bloc resection, will receive a single dose of 10

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Patient must have suspected HGD/T1RC and scheduled for a local endoscopic en-bloc resection. The rectum is defined as the area between the linea dentata and 10cm ab ano. 2. Age > 18 years old 3. Patients should be capable and willing to give signed informed consent before study specific procedures.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study 1. Prior participation in this study 2. Previous administration of SGM-101 3. Patients with a history of anaphylactic shock 4. Patients pregnant or breastfeeding, lack of effective contraception in male or female patients with reproductive potential 5. Any condition that the investigator considers to be potentially jeopardizing the patients* well-being or the study objectives.

Design outcomes

Primary

MeasureTime frame
Phase I/2: Primary endpoint is the ex-vivo fluorescence TDR (T1RC/HGD to LGD ratio).

Secondary

MeasureTime frame
- Ex-vivo NIR-fluorescence tumour-to-background ratio (TBR) and dysplasia-to-background ratio (DBR) (ex-vivo TDR already encountered within main objective) on whole specimen (Quest open camera, PEARL), bread loafs (Quest open camera and PEARL) and slides (dedicated 700nm microscopy scanner) - In-vivo TDR, TBR and DBR, as measured with the Quest spectrum laparoscope. - The accuracy of SGM-101 to discriminate T1RC/HGD from LGD ex-vivo on whole specimen (Quest open camera, PEARL), bread loafs (Quest open camera and PEARL) and slides (dedicated 700nm microscopy scanner). A TDR of >=1,5 is defined as true positive. A TDR of

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)